CARTITUDE-4: cilta-cel CAR-T versus standard combinations after one to three prior lines of myeloma therapy
Moving BCMA CAR-T to the second line cut the risk of progression or death by 74% compared with standard triplets, and later improved overall survival.
CARTITUDE-4 randomised 419 patients with lenalidomide-refractory multiple myeloma after one to three prior lines to a single infusion of ciltacabtagene autoleucel (after bridging therapy) or standard of care (pomalidomide-bortezomib-dexamethasone or daratumumab-pomalidomide-dexamethasone). The primary endpoint was PFS by intention to treat. At 12 months PFS was 75.9% versus 48.6% (hazard ratio 0.26); overall response was 84.6% versus 67.3%, complete response or better 73.1% versus 21.8%, and MRD-negativity 60.6% versus 15.6%. In later follow-up overall survival was significantly better with cilta-cel (hazard ratio about 0.55). Toxicity was manageable, with lower CRS and neurotoxicity rates than in CARTITUDE-1.
- 419 lenalidomide-refractory patients after 1-3 prior lines; cilta-cel vs PVd or DPd.
- 12-month PFS 75.9% vs 48.6%; hazard ratio 0.26 (intention-to-treat).
- Complete response or better 73.1% vs 21.8%; MRD-negativity 60.6% vs 15.6%.
- Overall survival significantly improved at second analysis (HR about 0.55).
- CRS in 76% of infused patients (grade 3-4 about 1%); ICANS about 5%; cranial nerve palsy and movement disorders in a small minority.
CARTITUDE-4 is the first randomised trial to show that a CAR-T improves survival in myeloma, and it moved cilta-cel into second-line use (FDA approval 2024). For patients whose disease returns after first-line lenalidomide, a one-off cell therapy now competes with continuous drug combinations. Capacity, cost and the need for bridging therapy still limit who actually receives it.
- Open-label; standard-of-care arm was a mix of two regimens, neither of which is the strongest available.
- Intention-to-treat analysis includes patients who progressed during bridging; per-protocol PFS is even more favourable.
- Only about 15% of standard-arm patients later received CAR-T, so the comparison is partly CAR-T now versus never.
- Secondary haematological malignancies and late neurotoxicity remain concerns.
KarMMa-3 was the first randomised evidence that CAR-T beats conventional drugs in myeloma and led to ide-cel's approval after two prior lines. It confirmed that earlier use of CAR-T produces deeper and longer remissions than in the end-stage setting. Because responses are shorter than with cilta-cel and OS was not improved, it also sharpened debate about which BCMA CAR-T to use and when.
CARTITUDE-1 showed that a single CAR-T infusion can put late-stage myeloma into deep, multi-year remission, leading to FDA approval of cilta-cel in 2022 for heavily pretreated disease. It set the efficacy bar for BCMA-directed therapy and motivated moving CAR-T earlier (CARTITUDE-4). Late neurological toxicity and secondary malignancies remain the safety questions.